Kristina Djekic1, Aram Mouzeyan, Eli Ipp. 1. Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California-Los Angeles Medical Center, David Geffen School of Medicine, 1000 West Carson Street, Torrance, California 90509, USA.
Abstract
CONTEXT: Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that has been classified as part of type 1 diabetes or as a distinct clinical entity. Its precise place as a disease category is therefore controversial. OBJECTIVE: The objective of this study was to further examine this issue by comparing the phenotypes of LADA and type 1 diabetes in a predominately minority population. PATIENTS AND METHODS: We studied 126 subjects who were anti-glutamic acid decarboxylase antibody-positive in two separate studies--63 subjects in an outpatient study (study 1), and 63 inpatients after resolution of ketoacidosis (study 2). Clinical and biochemical phenotyping was performed in all patients in each group. RESULTS: Few significant differences were found in the clinical or biochemical phenotypes in patients classified as LADA when compared with type 1 diabetes. Adiposity, body mass index, waist/hip ratio, fasting plasma C-peptide, serum high-density lipoprotein cholesterol, and triglycerides were all similar. The only distinguishing feature was a history of hypertension (study 1) or systolic blood pressure (study 2). Also, a history of ketoacidosis did not influence the phenotype of LADA in the outpatients in any discernable way. CONCLUSIONS: We conclude that LADA and type 1 diabetes are phenotypically indistinguishable in this predominantly minority population with a mean duration of glutamic acid decarboxylase antibody-positive diabetes of about 8 yr.
CONTEXT: Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that has been classified as part of type 1 diabetes or as a distinct clinical entity. Its precise place as a disease category is therefore controversial. OBJECTIVE: The objective of this study was to further examine this issue by comparing the phenotypes of LADA and type 1 diabetes in a predominately minority population. PATIENTS AND METHODS: We studied 126 subjects who were anti-glutamic acid decarboxylase antibody-positive in two separate studies--63 subjects in an outpatient study (study 1), and 63 inpatients after resolution of ketoacidosis (study 2). Clinical and biochemical phenotyping was performed in all patients in each group. RESULTS: Few significant differences were found in the clinical or biochemical phenotypes in patients classified as LADA when compared with type 1 diabetes. Adiposity, body mass index, waist/hip ratio, fasting plasma C-peptide, serum high-density lipoprotein cholesterol, and triglycerides were all similar. The only distinguishing feature was a history of hypertension (study 1) or systolic blood pressure (study 2). Also, a history of ketoacidosis did not influence the phenotype of LADA in the outpatients in any discernable way. CONCLUSIONS: We conclude that LADA and type 1 diabetes are phenotypically indistinguishable in this predominantly minority population with a mean duration of glutamic acid decarboxylase antibody-positive diabetes of about 8 yr.
Authors: Richard N Bergman; Darko Stefanovski; Thomas A Buchanan; Anne E Sumner; James C Reynolds; Nancy G Sebring; Anny H Xiang; Richard M Watanabe Journal: Obesity (Silver Spring) Date: 2011-03-03 Impact factor: 5.002
Authors: Harvey K Chiu; Elaine C Tsai; Rattan Juneja; James Stoever; Barbara Brooks-Worrell; Amit Goel; Jerry P Palmer Journal: Diabetes Res Clin Pract Date: 2007-01-17 Impact factor: 5.602
Authors: R D G Leslie; H Kolb; N C Schloot; R Buzzetti; D Mauricio; A De Leiva; K Yderstraede; C Sarti; C Thivolet; D Hadden; S Hunter; G Schernthaner; W Scherbaum; R Williams; P Pozzilli Journal: Diabetes Metab Res Rev Date: 2008-10 Impact factor: 4.876
Authors: Sinead Brophy; Knud Yderstraede; Didac Mauricio; Stephen Hunter; Mohammed Hawa; Paolo Pozzilli; Guntram Schernthaner; Nanette Schloot; Nanette Schoot; Raffaella Buzzetti; Helen Davies; David Leslie; Rhys Williams Journal: Diabetes Care Date: 2007-12-14 Impact factor: 19.112